Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Mediastinal radiotherapy after chemo for newly diagnosed primary mediastinal lymphoma

Andrew Davies • 19 Jun 2020
EHA 2020
B-Cell Lymphoma Lymphoma Antibodies Rituximab
IELSG 37

Andrew Davies, BSc, BM, MRCP, PhD, of the University of Southampton, Southampton, UK, discusses the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens in patients with newly diagnosed primary mediastinal large B-cell lymphoma as evaluated in the IELSG 37 study (NCT01599559). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrew Davies

Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
Economic burden of CAR-T therapy from a UK perspective 1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL 2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL 1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals